Introduction
One form of acute promyelocytic leukemia resistant to all-trans-retinoic acid therapy is found to be associated with the reciprocal chromosomal translocation t(11;17)(q23;q21). This event fuses the promyelocytic leukemia zinc-finger gene (PLZF) to the retinoic receptor-a gene (RARa) resulting in the expression of PLZF-RARa and RARa-PLZF fusion proteins (Chen et al., 1993; Costoya and Pandolfi, 2001 ). The PLZF gene encodes a highly conserved transcriptional repressor defined by the presence of a poxvirus and zinc-finger domain (POZ) at its N terminus, responsible for homodimerization and recruitment of transcriptional co-repressors, and nine Kru¨ppel-type C 2 H 2 zinc fingers located at the C terminus involved in binding to sequence-specific DNA sites. Besides having critical developmental functions (Barna et al., 2000 (Barna et al., , 2002 , PLZF is abundantly expressed in stem/progenitor cells of both the hematopoietic and male germ cell compartments and its expression levels decline upon differentiation suggesting that its downregulation may be required for the onset of terminal differentiation (Reid et al., 1995; Buaas et al., 2004; Costoya et al., 2004; Filipponi et al., 2007) . The biological roles of PLZF are likely to be associated with its potent growth-suppressive effects. In particular, overexpression of PLZF is demonstrated to cause accumulation of cells at the G 0 /G 1 cell cycle stage (Shaknovich et al., 1998; Yeyati et al., 1999) .
Mechanisms by which PLZF activity can be regulated through specific post-translational modifications, for example, by acetylation and conjugation to small ubiquitin-like modifier, have been characterized (Kang et al., 2003; Guidez et al., 2005; Chao et al., 2007) . However, PLZF has always been described as a phosphoprotein, and modulation of its function through this dynamic modification has not yet been elucidated. Importantly, BCL-6, an additional member of the POZKru¨ppel (POK) family of transcriptional repressors, is targeted for rapid degradation through its phosphorylation (Niu et al., 1998) .
Eukaryotic cell cycle progression is regulated by the sequential activation of cyclin-dependent kinases (CDKs) through association with specific cyclin partners and subsequent triggering of protein phosphorylation cascades. CDK2 activity plays an important role in G 1 /S progression by association with cyclin E in early G 1 and then cyclin A in late G 1 and early S phase (Sherr and Roberts, 1999; Malumbres and Barbacid, 2001) . Several transcription factors are among the known substrates of CDK2/cyclin complexes and this CDK-mediated phosphorylation can have diverse effects on their activity (Deed et al., 1997; Johnson et al., 1999; Rogatsky et al., 1999) . Given the dramatic effects of PLZF expression on cell cycle progression and its known modification by phosphorylation, we sought to determine whether PLZF is a target of CDK/cyclin activity and whether phosphorylation can impact on PLZF function.
Results

PLZF phosphorylation signature
To first verify PLZF phosphorylation in vivo two cell systems were used, that is, murine keratinocytes, which express detectable endogenous PLZF, and COS-1 cells transfected with a PLZF expression vector. Prior to protein extraction, cells were maintained in culture for 4 h in the presence of radiolabeled ortho-phosphate. Immunoprecipitated PLZF was found to be phosphorylated in both cell systems (Figure 1a) . To determine the nature of the phosphorylated residues, we performed phosphomapping analysis. A two-dimensional tryptic phosphopeptide map showed that PLZF was principally phosphorylated on Ser and Thr residues (Figure 1a ).
Phosphorylation of PLZF by CDK2
As PLZF was found to be phosphorylated, we analysed its primary structure and identified two consensus sites (S/T-P-X-K/R) for CDK-mediated phosphorylation (Ubersax and Ferrell, 2007) . It should be noted that other putative Ser, Thr and Tyr phosphorylation sites are predicted from the PLZF primary structure but we chose to focus on the potential role of CDK-mediated phosphorylation of PLZF (Figure 1b ). In addition, we could not detect any phosphoTyr signal in our phosphomapping analysis from the in vivo labeling. We subsequently performed in vitro kinase reactions on purified PLZF protein and found that immunoprecipitated active CDK2 can efficiently phosphorylate a glutathione S-transferase (GST)-PLZF fusion protein when compared to the control GST reaction (Figure 1c ). To determine whether PLZF is phosphorylated at the identified CDK-consensus sites, we generated a series of PLZF mutants, that is, S197A, T282A and S197A/T282A, in which one or both of these putative sites were mutated to Ala to block phosphorylation. The single mutants (S197A, T282A) were phosphorylated at lower levels than wild-type PLZF while phosphorylation was essentially abrogated in the double mutant (DM) (S197A/ T282A) (Figure 1c ) indicating that these two consensus sequences are the CDK2 phosphorylation sites within PLZF. These sites were mapped by two-dimensional electrophoresis to demonstrate the absence of the phospho-residues in the single mutants (Figure 1c ). It should be noted that PLZF could also be phosphorylated in vitro by active CDK1 albeit in a less efficient fashion than by CDK2 (data not shown).
Interestingly, the T282 phosphorylation motif represents a consensus site for both CDK and ERK MAPK-mediated phosphorylation (S/T-P-X-K/R and P-X-S/T-P, respectively) (Ubersax and Ferrell, 2007) . Therefore, to investigate whether ERK MAPK activity could also target T282, we performed an in vitro kinase reaction on immunoprecipitated wild type and S197A/ T282A DM PLZF isolated from transfected 293 HEK cells, using equivalent amounts of activated ERK and CDK2-cyclin A enzymes (Figure 1d ). Western blots prepared from the kinase reactions were probed with an antibody that specifically recognizes phosphorylated Thr only when followed by Pro (phospho-Thr MAPK/CDK substrate antibody) and as the T282 site is the only Thr-Pro motif within PLZF, we assessed phosphorylation of this residue alone. Transfected PLZF was found to contain detectable phosphorylation at T282 at the steady state while addition of activated ERK MAPK only resulted in a slight increase in its phosphorylation. However, addition of CDK2-cyclin A caused a substantial increase in T282 phosphorylation ( Figure 1d ) suggesting that CDKs rather than ERK MAPK may preferentially target T282. As a control, the PLZF DM did not react to the phospho-Thr-Pro antibody ( Figure 1d ).
CDK-mediated phosphorylation induces PLZF ubiquitination and degradation
To determine the role of CDK-mediated phosphorylation on PLZF function, 293 HEK cells were transfected with PLZF and PLZF DM constructs. Western blot analysis showed that in the presence of serum (cell cycle stimulated), the level of wild-type PLZF protein was reduced in comparison with the PLZF DM, while there was a similar amount of wild type and PLZF DM in serum-starved cells (cell cycle inhibited) ( Figure 2a ). To further assess the role of phosphorylation in regulation of PLZF stability, we analysed its half-life upon cycloheximide treatment. We observed that PLZF is stable for less than 2 h after initiation of cycloheximide treatment but that PLZF DM is degraded at a clearly decreased rate (Figure 2b ). These data suggest that phosphorylation of PLZF by a CDK activity decreases its stability. It is worth mentioning that while we cannot exclude the in vivo phosphorylation of alternative serine residues to S197 in these experimental conditions, mutation of these residues together with T282 in the PLZF DM eliminates the more slowly migrating likely hyperphosphorylated PLZF band that we observe by western blot (Figure 2b ). This suggests that these are the principal phosphorylation sites within PLZF.
The CDK phosphorylation sites identified within PLZF were found to be contained in a region rich in Pro, Glu, Asp, Ser and Thr residues, within which we identified four typical PEST sequences (Figure 1b) , regions known to act as signals for proteolytic degradation (Rechsteiner and Rogers, 1996) . The presence of these PEST sequences suggested that CDK-induced phosphorylation of PLZF might induce its degradation by the ubiquitin/proteosome pathway. To this end we tested whether PLZF-ubiquitin conjugates could be detected in cells by co-transfecting vectors containing PLZF or PLZF DM alongside HA-tagged ubiquitin. Immunoprecipitation with anti-PLZF antibodies and western blot analysis using anti-HA antibodies produced typical ladders representing multi-ubiquitinated forms of PLZF, which were largely absent with the PLZF DM mutant form as expected (Figure 2c ).
PLZF phosphorylation does not affect its subcellular localization
As an additional control, we checked whether phosphorylation of PLZF upon CDK activation altered the subcellular distribution of PLZF (Nanba et al., 2003; Senbonmatsu et al., 2003) . Using enhanced green fluorescent protein (EGFP)-tagged versions of PLZF wild type and the DM for confocal analysis and the regular untagged constructs for fractionation experiments followed by western blot analysis, we show that stimulation of cells with the growth-factor mimetic 12-O-tetradecanoylphorbol-13-acetate (TPA) induced a reduction in the levels of wild-type PLZF, which is markedly diminished in the case of the PLZF DM (Figure 2d ). However, in either case TPA did not induce an overall redistribution of PLZF in the cytoplasm and the nucleus (Figure 2d ). These data suggested that CDK-induced phosphorylation triggers degradation of PLZF via the ubiquitin/proteosome pathway without causing a significant alteration in its subcellular distribution. It should also be noted that the confocal analysis of PLZF subcellular localization shows a predominantly nuclear signal but by cellular fractionation and western blot PLZF appears mostly cytosolic. Therefore, while each method demonstrates that PLZF is found both in the cytoplasm and the nucleus, it is likely that during the cellular fractionation process a quantity of the transfected Plzf leaks into the cytoplasmic fraction. Irrespective, both methods confirm that PLZF is not redistributed in response to activation of CDKs.
Phosphorylation of PLZF at the CDK consensus sites impairs its function
To demonstrate the physiological significance of CDK-mediated phosphorylation/degradation of PLZF, and a-tubulin was used to determine purity of nuclear and cytoplasmic samples, respectively. Increased phospho-ERK1/2 levels demonstrate response to TPA treatment.
CDK2-mediated phosphorylation of PLZF
JA Costoya et al we explored the effect of this modification on the role of PLZF as a transcriptional repressor and on cell cycle control. We therefore employed a reporter construct containing a consensus site previously reported to be bound by PLZF (Li et al., 1997) . The PLZF DM was found to exhibit a stronger repressive activity than the wild-type protein on the reporter construct (Figure 3a) suggesting that phosphorylation-dependent regulation of PLZF stability can negatively affect its transcriptional repressive function. We next analysed the proliferation of murine keratinocytes obtained from PLZF null and control littermates (Barna et al., 2000) to investigate cell cycle effects. A H 3 -thymidine incorporation assay showed a clear increase in incorporation by the PLZF mutant keratinocytes when compared to controls (Figure 3b) confirming that PLZF plays a negative role on cell cycle progression. To determine at which point in the cell cycle PLZF may be able to induce arrest, we co-transfected an expression plasmid encoding PLZF wild type or DM together with a plasmid encoding farnesyl-EGFP, which allows identification of transfected cells by flow cytometry. Staining of transfected cells for DNA showed that expression of wildtype PLZF leads to accumulation at the G 1 /S transition of the cell cycle and that this cell cycle arrest was further enhanced when PLZF DM was expressed (Figure 3c ).
To test whether the mechanism of enhanced growth suppression by PLZF DM also operated in transformed cells, we introduced both PLZF and PLZF DM constructs together with a puromycin resistance cassette by transient transfection into two different tumor cell lines (U2-OS and H1279). After selection, the number of resistant colonies was determined (Figures 4a and b) . Expression of PLZF inhibited colony formation in both cell lines as expected but when PLZF phosphorylation is blocked by expression of PLZF DM, colony formation was inhibited even further. This confirms that PLZF DM is a more potent growth inhibitor than the wildtype protein and that PLZF phosphorylation may be relevant for the ability of tumor cells to escape cell cycle control.
Discussion
CDK/cyclin complexes are widely believed to phosphorylate proteins whose activities are essential for traversing cell cycle boundaries (Sherr and Roberts, 1999; Malumbres and Barbacid, 2001 ). Thus, to understand the molecular mechanisms that regulate cell proliferation, it is fundamental to identify the substrates whose activities are regulated by CDKs. In this study, we demonstrate that PLZF is phosphorylated by CDK2 and that this phosphorylation regulates the function of PLZF by altering its stability. This finding suggests that PLZF plays a key role in the control of cell proliferation as our data now conclusively demonstrates. Intriguingly, one of the partner cyclins of CDK2 (cyclin A2) is known to be transcriptionally repressed by PLZF (Yeyati et al., 1999) . Our data imply that through the inactivation of PLZF, CDK2 would increase the expression of cyclin A2, which in turn potentiates its activity, creating a positive feedback loop (Figure 4c ).
High levels of PLZF are expressed in the immature cellular compartments of both the hematopoietic and spermatogonial systems and PLZF levels decline upon differentiation, leading to the notion that PLZF expression maintains immature, progenitor cells in a relatively quiescent state prior to the differentiation process (Piazza et al., 2004) . Indeed, quiescence has emerged as a key factor for the maintenance of stem cell potential (Hock et al., 2004; Zhang et al., 2006) , and at least in the male germ cell system, PLZF is known to be required for stem cell function (Buaas et al., 2004; Costoya et al., 2004) . The present study thus perfectly illustrates the intimate ties between PLZF and cell cycle progression likely critical for its ability to maintain stem cell compartments.
Materials and methods
Cell culture and transfection assays COS, NIH-3T3 and 293 HEK cells were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% FBS, 2 mM glutamine penicillin/streptomycin at 37 1C in 5% CO 2 . Cells were transfected using Fugene 6 (Roche, Indianapolis, IN, USA) or lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). A dual-luciferase reporter assay system (Promega, Madison, WI, USA) was used to perform promoter reporter assays, normalizing to thymidine kinase-Renilla.
Plasmids
Site-directed mutagenesis of PLZF was performed using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's suggestions. Templates used were PLZF cDNA cloned into pSG5 (Stratagene) and pGEX5 (Amersham/Pharmacia, Piscataway, NJ, USA) for GST fusion proteins. Wild-type PLZF and S197A/T282A DM constructs were subcloned into the EcoRI site of pcDNA3.1HisB (Invitrogen) to tag with the Xpress (XP) epitope. Constructs were verified by sequencing.
Purification of GST fusion proteins
Fusion proteins were isolated as described by the manufacturer's instructions (Amersham/Pharmacia). GST-PLZF and related mutants were affinity-purified with glutathione-sepharose beads before use for in vitro kinase assays.
[ 32 P] labeling and PLZF immunoprecipitation Subconfluent COS cells and murine keratinocytes were labeled with 5 mCi ml À1 of HCl-free [ 32 P]orthophosphate (Amersham, Piscataway, NJ, USA) in phosphate-free DMEM (Gibco-BRL, Carlsbad, CA, USA). Primary murine keratinocytes were maintained in culture as previously described (Brissette et al., 1991) . Labeling proceeded for 4 h, starting 48 h after transfection (COS cells). Protein extracts were prepared and used for immunoprecipitation using PLZF polyclonal antibody as described (Barna et al., 2002) . Immunoprecipitated protein was resolved on a 7.5% SDS-PAGE, blotted onto Protan (S&S, New Jersey, NJ, USA) and visualized by autoradiography.
In vitro kinase assays CDK2 in vitro kinase assays were performed as described (Koff et al., 1991) . Cell lysates were precleared with Lysates prepared from 293 HEK cells transfected with XP-PLZF or XP-PLZF DM constructs (48 h post transfection) were subject to immunoprecipitation with anti-XP antibody followed by collection with protein G sepharose. Immunocomplexes were washed twice in lysis buffer and then once in kinase reaction buffer (NEB) before resuspension in reaction buffer supplemented with 200 mM ATP alone plus recombinant activated p42 MAPK or recombinant CDK2-cyclin A (New England Biolabs, Ipswich, MO, USA: 100 U per reaction) and incubated for 30 min at 30 1C. Immunocomplexes were washed twice more in lysis buffer and then processed for western blot as described above. Membranes were probed with a phosphoThr MAPK/CDK substrate mouse mAb (Cell Signaling, Danvers, MA, USA). Secondary antibody was donkey anti-mouse IgM HRP conjugate (Jackson Immunolabs, West Grove, PA, USA). Additional antibodies for western blot included Hsp90 (BD Bioscience, San Jose, CA, USA), XP tag (Invitrogen), HA tag (Covance, Emeryville, CA, USA), HDAC1 (Upstate Biotechnology, Billerica, MA, USA), tubulin (Sigma) and phospho-ERK (Cell Signaling).
Two-dimensional phosphopeptide mapping
Immunoprecipitated [
32 P]PLZF and GST fusion proteins were blotted and visualized as described above. Excised bands were subjected to two-dimensional tryptic phosphopeptide mapping as described elsewhere (Bonifacino et al., 2000) .
